The invention is directed to compositions containing physiologically active compounds of general formula (I) wherein R<1> is aryl or heteroaryl; R<2> represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z<1>R<8>,-C(=O)-NY<3>Y<4>,-CO2R<8>,-NY<3>Y<4>,-N(R<6>)-C(=O)-R<7>, -N(R<6>)-C(=O)-NY<3>Y<4>,-N(R<6>)-C(=O)-OR<7>, -N(R<6>)-SO2-R<7>,-N(R<6>)-SO2-NY<3>Y<4> and one or more halogen atoms; R<3> represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -C(=O)-OR<5> or -C(=O)-NY<3>Y; and X<1> represents N, CH, C-halo, C-CN, C-R<7>, C-NY<3>Y<4>, C-OH, C-Z<2>R<7>, C-C(=O)-OR<5>, C-C(=O)-NY<3>Y<4>, C-N(R<8>)-C(=O)-R<7>, C-SO2-NY<3>Y<4>, C-N(R<8>)-SO2-R<7>, C-alkenyl, C-alkynyl or C-NO2; and their produgs, and pharmaceutically acceptable salts and solvates of such compounds and their produgs, as well as to novel compounds within the scope of fomula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases. |